Additionally, combinations of neratinib with multi-kinase inhibitors like dasatinib or with downstream signaling inhibitors, such as mTOR and CDK4/6 inhibitors, have demonstrated strong preclinical efficacy by suppressing key survival pathways in HER2-positive breast cancer models [54,55]. Here, CDK4 is linked to breast carcinoma.